Benjamin Yerxa, PhD

Dr. Yerxa is President of Envisia Therapeutics, a spin out of Liquidia Technologies. Previously, he was the CSO for both Liquidia and Envisia and joined Liquidia from Clearside Biomedical. Prior to Clearside, Dr. Yerxa was the Executive Vice President and Chief, Research & Development of Inspire Pharmaceuticals (ISPH). He is an inventor of DIQUAS™, an innovative treatment for dry eye approved in Japan. Dr. Yerxa has more than 50 U.S. patents to his name, led a variety of licensing deals and technology transfers, and has built several R&D and corporate functions from inception.